Oruka Therapeutics
ORKA
15 hedge funds and large institutions have $12.3M invested in Oruka Therapeutics in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 0 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
7% more funds holding
Funds holding: 14 → 15 (+1)
0.01% more ownership
Funds ownership: 0.25% → 0.25% (+0.01%)
1% less capital invested
Capital invested by funds: $12.4M → $12.3M (-$111K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$359K |
| 2 |
ACP
Aveo Capital Partners
Englewood,
Colorado
|
+$110K |
| 3 |
Renaissance Technologies
New York
|
+$57.4K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$33.9K |
| 5 |
Morgan Stanley
New York
|
+$521 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$119K |
| 2 |
BlackRock
New York
|
-$36.5K |
| 3 |
Goldman Sachs
New York
|
-$1.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $3.5M | – | – | – |
|
2
Franklin Resources
San Mateo,
California
| $2.98M | – | – | – |
|
|
VMI
3
VHCP Management II
New York
| $2.59M | – | – | – |
|
|
TCM
4
Tekla Capital Management
Boston,
Massachusetts
| $1.99M | – | – | – |
|
|
RA
5
Royce & Associates
New York
| $441K | +$359K | +689 | +478% |
|
|
ACP
6
Aveo Capital Partners
Englewood,
Colorado
| $225K | +$110K | +210 | +94% |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| $177K | -$119K | -228 | -40% |
|
|
8
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $144K | +$33.9K | +65 | +30% |
|
|
9
Renaissance Technologies
New York
| $130K | +$57.4K | +110 | +77% |
|
|
10
Goldman Sachs
New York
| $39K | -$1.04K | -2 | -3% |
|
11
Northern Trust
Chicago,
Illinois
| $26K | – | – | – |
|
12
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $25K | – | – | – |
|
|
13
BlackRock
New York
| $2K | -$36.5K | -70 | -95% |
|
14
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
15
Morgan Stanley
New York
| $1K | +$521 | +1 | New |
|
ORKA Hedge Fund Activity: Q2 2017 in Review
15 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2017, worth a combined $12.3M — down 0.9% from $12.4M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ORKA positions and 0 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Royce & Associates, adding an estimated $359K. The largest seller was Vanguard Group, cutting an estimated $119K.
- 15 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2017, up from 14 in Q1 2017.
- Funds reported $12.3M of Oruka Therapeutics stock for Q2 2017, down 0.9% quarter-over-quarter.
- 1 fund opened new Oruka Therapeutics positions in Q2 2017 and 0 closed out, a net change of +1 holder.
- The largest Oruka Therapeutics buyer in Q2 2017 was Royce & Associates, an estimated $359K added.
- The largest Oruka Therapeutics seller in Q2 2017 was Vanguard Group, an estimated $119K sold.
Based on aggregated 13F filings for Q2 2017.